• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » NeuroMetrix returns MLSC tax incentive funds

NeuroMetrix returns MLSC tax incentive funds

January 26, 2011 By MassDevice staff

NURO logo

NeuroMetrix Inc. (NSDQ:NURO) and two other companies re-paid tax incentives to Massachusetts after failing to create enough jobs to meet the demands of the deal through which the funding came.

The Waltham, Mass.-based company, which has suffered sinking revenues over the past year, voluntarily surrendered the $300,000 that it procured through the Mass. Life Sciences Center’s $25 million Tax Incentive Program in late 2009, according to a center spokesman.

As part of the incentive program, NeuroMetrix committed to add 10 employees to its workforce by the close of 2010, but three consecutive quarters of decreasing sales, which were accompanied by a delisting warning from NASDAQ and major investor divestitures, made new hires unfeasible for the neurodiagnostics developer. In early January, the company laid off 27 percent of its workers, disbanded its sales operation and announced the planned phase out of its flagship product, the NC-stat.

Framingham, Mass.-based GTC Biotherapeutics Inc. also returned the $300,000 it received in 2009 through MLSC tax incentives for the creation of 10 jobs, according to the spokesman.

Genzyme Corp. (NSDQ:GENZ) returned the $6 million that the state provided the company to add 200 new jobs, according to MLSC. Although the it was able to meet those demands, two divestitures reduced its workforce significantly. The Cambridge, Mass.-based biotechnology firm sold off its diagnostics business to Sekisui Chemical Co. Ltd. (TYO:4204) for $265 million and offloaded the Genzyme Genetics unit to Laboratory Corporation of America Holdings (NYSE:LH) in a transaction valued at $925 million.

The MLSC won’t know whether all 28 companies that participated in the 2009 incentive program met its job creation requirements until Feb 1.

InfraReDx Inc., Interlace Medical, Inc., Lightlab Imaging Inc., Merrimack Pharmaceuticals, Nova Biomedical Corp., Organogenesis, Shire HGT Inc., Still Rivers Systems Inc. and Sunovion Inc. (formerly Sepracor Inc.) all made enough of an increase to their staffing numbers to have met the program’s demands, according to the spokesman. Each one of the companies won tax incentives in late 2010 as part of the MLSC’s $24 million round for 2011.

Filed Under: Business/Financial News, News Well Tagged With: Genzyme Corp., Mass. Life Sciences Center (MLSC), Neurometrix

More recent news

  • Medtronic earns CE mark for redo TAVI procedure
  • Natus Neuro launches BrainWatch AI-driven, point-of-care EEG
  • Boston Scientific has positive real-world Acurate Prime TAVI data
  • Johnson & Johnson MedTech launches ultrasound catheter for imaging in cardiac ablation procedures
  • Onward reports more successful BCI implants

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy